HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

J Antimicrob Chemother. 2014 Aug;69(8):2191-4. doi: 10.1093/jac/dku119. Epub 2014 Apr 30.

Abstract

Background: HIV-2 infection is characterized by low plasma viraemia and slower progression to AIDS in comparison with HIV-1 infection. However, antiretroviral therapy in patients with HIV-2 is less effective and often fails to provide optimal CD4 recovery.

Methods: We examined viral tropism in persons with HIV-2 infection enrolled in the HIV-2 Spanish cohort. Viral tropism was estimated based on V3 sequences obtained from plasma RNA and/or proviral DNA.

Results: From a total of 279 individuals with HIV-2 infection recorded in the Spanish national register, 58 V3 sequences belonging to 42 individuals were evaluated. X4 viruses were recognized in 14 patients (33%). Patients with X4 viruses had lower median CD4+ cell counts than patients with R5 viruses [130 (17-210) versus 359 (180-470) cells/mm(3); P = 0.007]. This was true even considering only the subset of 19 patients on antiretroviral therapy [94 (16-147) versus 184 (43-368) cells/mm(3); P = 0.041]. In multivariate analysis, significant differences in CD4+ cell counts between patients with X4 and R5 viruses remained after adjusting for age, gender, antiretroviral therapy and viral load.

Conclusions: The presence of X4-tropic viruses in HIV-2 infection is associated with low CD4+ cell counts, regardless of antiretroviral treatment. Along with CD4+ cell counts, viral tropism testing may assist decisions about when to initiate antiretroviral therapy in HIV-2-infected individuals.

Keywords: CCR5 antagonists; maraviroc; proviral load.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • CCR5 Receptor Antagonists / therapeutic use
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology*
  • Cyclohexanes / therapeutic use
  • Female
  • HIV Envelope Protein gp120 / blood
  • HIV Fusion Inhibitors / therapeutic use
  • HIV Infections / blood
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV-2 / classification
  • HIV-2 / immunology
  • HIV-2 / physiology*
  • Humans
  • Male
  • Maraviroc
  • Middle Aged
  • Peptide Fragments / blood
  • RNA, Viral / blood
  • Spain
  • Triazoles / therapeutic use
  • Viral Load
  • Viral Tropism / immunology
  • Viral Tropism / physiology*
  • Viremia / blood

Substances

  • Anti-HIV Agents
  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • HIV Envelope Protein gp120
  • HIV Fusion Inhibitors
  • HIV envelope protein gp120 (305-321)
  • Peptide Fragments
  • RNA, Viral
  • Triazoles
  • Maraviroc